Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03146533 | CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 20 | Shenzhen Second People's HospitalOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03156933 | Alternative Splicing and Leukemia Initiating Cells(ASLIC) | unknown | — | 500 | Hospices Civils de LyonOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03154775 | Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | unknown | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | May 16, 2017 | clinicaltrials |
| NCT03150134 | Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients | unknown | Phase 4 | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03150602 | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | unknown | Phase 4 | 22 | Taiwan Mundipharma Pharmaceuticals Ltd.INDUSTRY | 1 | May 12, 2017 | clinicaltrials |
| NCT03150849 | C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia | unknown | — | 50 | Assiut UniversityOTHER | 0 | May 12, 2017 | clinicaltrials |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | unknown | Phase 3 | 408 | FENG Ji-fengOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT03121625 | CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03122327 | cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study. | unknown | — | 200 | Peking Union Medical College HospitalOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT03123718 | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL | unknown | Phase 3 | 205 | Chonnam National University HospitalOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT03118180 | CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02493829 | B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) | unknown | Phase 1 | 10 | King's College LondonOTHER | 0 | Apr 13, 2017 | clinicaltrials |
| NCT03105596 | Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | unknown | Phase 2 | 46 | Peking UniversityOTHER | 0 | Apr 11, 2017 | clinicaltrials |
| NCT03107962 | Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma | unknown | Phase 2 | 20 | Mingzhi ZhangOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT03062072 | Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients(ECHO) | unknown | — | 300 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 7, 2017 | clinicaltrials |
| NCT03101709 | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | unknown | Phase 1 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 5, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT03000738 | The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 31, 2017 | clinicaltrials |
| NCT03079947 | Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT03089411 | Collection of Additional Data Followed the Study IFM 2013-04 | unknown | — | 340 | Nantes University HospitalOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02728882 | Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma(EECBL) | unknown | N/A | 24 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Mar 23, 2017 | clinicaltrials |
| NCT03086954 | Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma(EECPL) | unknown | Phase 1 | 24 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Mar 22, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02912754 | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | unknown | Phase 1 / Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02721407 | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients(MendCART) | unknown | Phase 1 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL(MCLelderly) | unknown | Phase 3 | 570 | European Mantle Cell Lymphoma NetworkOTHER | 7 | Mar 7, 2017 | clinicaltrials |
| NCT01449344 | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL((R-HAD)) | unknown | Phase 3 | 128 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 2 | Mar 7, 2017 | clinicaltrials |
| NCT03054532 | Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma | unknown | Phase 2 | 22 | Singapore General HospitalOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT02863302 | Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients | unknown | N/A | 50 | Rambam Health Care CampusOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT02087657 | Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation(Auto-HBO) | unknown | N/A | 20 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02955628 | RICE-ibrutinib in Relapsed DLBCL | unknown | Phase 2 | 34 | Singapore General HospitalOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT03051542 | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03051555 | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03051568 | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma | unknown | N/A | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03051581 | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma | unknown | N/A | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02572596 | Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients | unknown | N/A | 200 | Wang GuorongOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02916459 | EBUS-TBNA vs Flex 19G EBUS-TBNA | unknown | N/A | 250 | Heidelberg UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03023384 | Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML(ICAML2015) | unknown | — | 547 | International Consortium on Acute LeukemiasOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT03035344 | Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) | unknown | — | 25 | Aristotle University Of ThessalonikiOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02474550 | Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma | unknown | — | 1,000 | Ajou University School of MedicineOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02979548 | Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | unknown | Phase 3 | 116 | Dr Atul SharmaOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL(CCFMPCA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
Data updated 24 days agoSource updated May 17, 2017source: clinicaltrials